Clinical Development of Respiratory Syncytial Virus Antivirals—What We Can Learn From Oseltamivir.

The article discusses respiratory syncytial virus has a major cause of morbidity and mortality for specific risk groups, including infants with or without comorbidities, older adults, and immunocompromised patients. Topics include challenges in drug delivery such as poor tolerability and potential toxicity of ribavirin have a major limitation; and respiratory syncytial virus antiviral agents that have being developed divided into different therapeutic classes.